EZH2: a novel target for cancer treatment
R Duan, W Du, W Guo - Journal of hematology & oncology, 2020 - Springer
Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …
AMPK: restoring metabolic homeostasis over space and time
E Trefts, RJ Shaw - Molecular cell, 2021 - cell.com
The evolution of AMPK and its homologs enabled exquisite responsivity and control of
cellular energetic homeostasis. Recent work has been critical in establishing the …
cellular energetic homeostasis. Recent work has been critical in establishing the …
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Epigenetic mechanisms play vital roles not only in cancer initiation and progression, but also
in the activation, differentiation and effector function (s) of immune cells. In this review, we …
in the activation, differentiation and effector function (s) of immune cells. In this review, we …
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
J Yuan, X Dong, J Yap, J Hu - Journal of hematology & oncology, 2020 - Springer
Cancer is characterized as a complex disease caused by coordinated alterations of multiple
signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined …
signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined …
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
Y Hua, Y Zheng, Y Yao, R Jia, S Ge… - Journal of Translational …, 2023 - Springer
Metformin is a well-known anti-diabetic drug that has been repurposed for several emerging
applications, including as an anti-cancer agent. It boasts the distinct advantages of an …
applications, including as an anti-cancer agent. It boasts the distinct advantages of an …
Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer
S Kitajima, E Ivanova, S Guo, R Yoshida, M Campisi… - Cancer discovery, 2019 - AACR
KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
Mechanisms of Polycomb group protein function in cancer
V Parreno, AM Martinez, G Cavalli - Cell research, 2022 - nature.com
Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …
ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer
Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …
leads to the emergence of resistant tumors characterized by lineage plasticity and …
[HTML][HTML] SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways
H Yuan, Y Han, X Wang, N Li, Q Liu, Y Yin, H Wang… - Cancer cell, 2020 - cell.com
The level of SETD2-mediated H3K36me3 is inversely correlated with that of EZH2-catalyzed
H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are …
H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are …